Khớp | Medical News | MIMS Vietnam

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

Jairia Dela Cruz, 20231205140000

For older adults with chronic kidney disease (CKD) who are initiating a disease-modifying antirheumatic drug (DMARD), low-dose methotrexate appears to be associated with a heightened 90-day risk of serious adverse events compared with hydroxychloroquine, as shown in a study.

Inflammation, disease duration and delayed diagnosis associated with hypertension in axial spondyloarthritis

Natalia Reoutova, 20231205000000

Axial spondyloarthritis (axSpA) patients with a higher inflammatory burden, longer delay in diagnosis and longer baseline disease duration (BLDD) have an increased risk of developing incident hypertension after adjusting for traditional cardiovascular (CV) risk factors, a retrospective cohort study by the Chinese University of Hong Kong has shown.

Original New Drug Application Approvals by US FDA (16-31 October 2023)

20231108090440

New drug applications approved by US FDA as of 16-31 October 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Dalbavancin an effective treatment option for serious gram-positive infections

Audrey Abella, 20231023100000

In a real-world study presented at IDWeek 2023, dalbavancin has been shown to be an effective treatment alternative for patients with invasive gram-positive infections.

Ustekinumab biosimilar shows clinical similarity to reference drug for plaque psoriasis

Audrey Abella, 20231019100000

A phase III study presented at EADV 2023 demonstrated the similarity between SB17, a human monoclonal antibody and proposed ustekinumab biosimilar, and reference ustekinumab for the treatment of moderate-to-severe plaque psoriasis.

Original New Drug Application Approvals by US FDA (01-15 October 2023)

20231018081105

New drug applications approved by US FDA as of 01-15 October 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Prednisolone ≥5 mg/day doubles risk of MACE in RA patients

Christina Lau, 20231017043557

In patients with rheumatoid arthritis (RA), use of systemic glucocorticoids (GC) is associated with a time- and dose-dependent increase in risk of major adverse cardiovascular events (MACE), a population-based real-world study has shown. On long-term follow-up, a prednisolone dose of ≥5 mg/day is associated with a doubled risk of MACE vs no GC use, and no safe duration of use is found for this daily GC dose.

Original New Drug Application Approvals by US FDA (15-30 September 2023)

20231010092042

New drug applications approved by US FDA as of 15-30 September 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Sex, ethnicity, comorbidity tied to poor gout control prevalence in SG

Jairia Dela Cruz, 20231006140000

In Singapore, poorly controlled gout appears to be common among men, Malays, and individuals with congestive cardiac failure, as reported in a study.

Renal relapse in childhood-onset lupus nephritis: When? Who’s at risk?

Sarah Cheung, 20231006080000

A 20-year retrospective study in Hong Kong has shown that renal relapse generally occurs within the first 5 years after diagnosis of childhood-onset lupus nephritis (cLN) in Chinese patients. The risk of renal relapse is higher in those diagnosed at young age, those failing to achieve complete remission (CR) 12 months after induction therapy, and those receiving maintenance therapy other than mycophenolate mofetil (MMF).